Vicarious Surgical Announces Launch of Proposed Public Offering
- None.
- None.
Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Vicarious Surgical intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for funding of ongoing operations, including the development of our single-port surgical robot, called the Vicarious Surgical System, and other general corporate purposes.
A registration statement on Form S-3 relating to these securities was filed with the Securities and Exchange Commission (“SEC”) on October 7, 2022, and was declared effective by the SEC on October 27, 2022. The offering is being made only by means of a preliminary prospectus supplement and accompanying prospectus which will be filed with the SEC relating to and describing the terms of the proposed offering and will be available on the SEC’s website at www.sec.gov. You can also obtain the preliminary prospectus supplement and accompanying prospectus, when available, by contacting Morgan Stanley & Co. LLC at Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by a strong investor base. The Company is headquartered in
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the proposed underwritten offering, including Vicarious Surgical’s expectations with respect to completion, timing and size of the proposed offering, the underwriters’ exercise of the option to purchase additional shares, and the use and application of the estimated net proceeds. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: market conditions at the time of the proposed offering, the ability to recognize the benefits of Vicarious Surgical’s business combination, which may be affected by, among other things, competition and its ability to grow and manage growth profitably and retain its key employees; the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the success, cost and timing of Vicarious Surgical’s product and service development activities; the regulatory clearance, authorization or approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of Vicarious Surgical’s single-port surgical robot, called the Vicarious Surgical System, and any of Vicarious Surgical’s future product candidates and service offerings; the potential attributes and benefits of the Vicarious Surgical System and any of Vicarious Surgical’s other product and service offerings once commercialized; Vicarious Surgical’s ability to obtain and maintain regulatory clearance, authorization, or approval for the Vicarious Surgical System and its product and service offerings on the timeline Vicarious Surgical expects, and without unexpected restrictions and limitations of any authorized product or service offering; changes in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802371640/en/
Vicarious Surgical Contact:
Kaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Source: Vicarious Surgical Inc.
FAQ
What is the ticker symbol of Vicarious Surgical Inc.?
What is the purpose of the public offering announced by Vicarious Surgical Inc.?
Who are the joint book-running managers for the offering?
Where can I find more information about the offering?